Blue light aminolevulinic acid photodynamic therapy downregulates cell division and proliferation pathways in cutaneous squamous cell carcinoma

Evan Austin,Jessica Mineroff,Isabella Dana,Jared Jagdeo
DOI: https://doi.org/10.1002/jbio.202300369
IF: 3.3899
2024-02-09
Journal of Biophotonics
Abstract:5‐Aminolevulinic acid (5‐ALA) photodynamic therapy (PDT) is a treatment for actinic keratosis and has been studied as a treatment for noninvasive cutaneous squamous cell carcinoma (cSCC). In this study, differential gene expression and pathway analysis of cSCC and human dermal fibroblasts were compared before and after 5‐ALA blue light PDT using RNA sequencing. Pathways associated with proliferation and carcinogenesis were downregulated, indicating that surviving residual cells may undergo changes consistent with a less aggressive cancerous phenotype. 5‐Aminolevulinic acid (5‐ALA) photodynamic therapy (PDT) is a treatment for actinic keratosis (AK) and has been studied as a treatment for noninvasive cutaneous squamous cell carcinoma (cSCC). PDT induces apoptosis and necrosis in AKs and cSCC. 5‐ALA blue light PDT may modulate gene expression and pathways in surviving cells. In this study, differential gene expression and pathway analysis of cSCC and human dermal fibroblasts were compared before and after 5‐ALA blue light PDT using RNA sequencing. No genes were differentially expressed after correcting for multiple testing (false discovery rate
optics,biochemical research methods,biophysics
What problem does this paper attempt to address?